|Bid||71.20 x 1100|
|Ask||71.21 x 900|
|Day's range||69.64 - 71.40|
|52-week range||60.89 - 85.97|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||N/A|
|Earnings date||22 Oct 2020 - 26 Oct 2020|
|Forward dividend & yield||2.72 (3.91%)|
|Ex-dividend date||14 Sep 2020|
|1y target est||80.17|
Gilead Sciences (NASDAQ: GILD) and Pfizer (NYSE: PFE) are two of the most competent pharmaceutical companies in the industry. Recently, Gilead has been in the headlines thanks to its much-discussed antiviral drug remdesivir, which appears to be somewhat beneficial for treating coronavirus infections in certain patient populations. It helps that Gilead was an attractive company well before the pandemic, with normalized trailing 12-month diluted earnings per share (EPS) of $3.90 in contrast with Pfizer's $1.98 and a robust profit margin of 21.8%, slightly trailing Pfizer's 28.8%.
Although it isn't particularly famed as a dividend stock, Gilead Sciences (NASDAQ: GILD) is nevertheless a consistent payer of such distributions. Reinforcing this, the company -- these days considered a coronavirus stock due to its COVID-19 drug remdesivir -- has declared its latest quarterly dividend. On Friday's closing stock price, this would yield 3.9%.
The stock market has seen internal discord for quite a while, but the Nasdaq Composite (NASDAQINDEX: ^IXIC) hasn't shown any signs of slowing down. Much of the gains came from the biggest tech stocks listed on the Nasdaq, with Apple (NASDAQ: AAPL) in particular climbing sharply on strong earnings and its announcement of a pending 4-for-1 stock split. Both Gilead Sciences (NASDAQ: GILD) and Moderna (NASDAQ: MRNA) were lower on Friday, weighed down by competitive fears on the coronavirus vaccine and by company-specific factors affecting their businesses.
Gilead said it expects total 2020 sales of $23 billion to $25 billion, up from its previous range of $21.8 billion to $22.2 billion. "We think this implies up to $1 billion to $3 billion of remdesivir, ... a positive that was not expected at the start of the year," said Jefferies analyst Michael Yee. Gilead's second-quarter sales fell nearly 10% from a year earlier to $5.1 billion, short of the average analyst estimate of $5.3 billion, according to Refinitiv.
On the surface, Gilead Sciences' (NASDAQ: GILD) second quarter was ugly. Sales decreased 10% in the second quarter to $5.1 billion, with Gilead's hepatitis C drug franchise contributing to most of the decline, down a whopping 47% year over year. Sales of Gilead's HIV franchise, which has been the backbone of the biotech, fell 1% in the second quarter.
Gilead (GILD) delivered earnings and revenue surprises of -23.97% and -1.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.68 per share of common stock for the third quarter of 2020. The dividend is payable on September 29, 2020, to stockholders of record at the close of business on September 15, 2020. Future dividends will be subject to Board approval.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter and first half 2020.
Diodes Incorporated (NASDAQ: DIOD) today announced its first precision operational amplifier. The AS2333 uses chopper stabilization to achieve ultra-low input offset voltage of 8µV (typical) and near-zero drift (0.02µV/degree C, typical) over time and temperature. The chopper stabilization also addresses low frequency 1/f noise and offset voltage crossover distortion. Typical applications for the AS2333 include transducers, medical equipment, chemical detectors, and handheld test instruments.
Gilead Sciences, Inc. (Nasdaq: GILD) and the Satcher Health Leadership Institute at Morehouse School of Medicine are working together to develop a real-time, public-facing and comprehensive health equity data platform to help address the impact of COVID-19 and other diseases on communities of color.
Synairgen's (LSE: SNG) stock skyrocketed on Monday amid news that the largely unknown British respiratory therapeutics company had demonstrated in a phase 2 clinical trial that its inhalable drug SNG001 reduced the chances of coronavirus patients needing a ventilator by a stunning 79%. While the results are still preliminary and need robust third-party confirmation, investors are already curious about whether SNG001 poses a threat to established competitors in the coronavirus therapeutics space, like Gilead Sciences (NASDAQ: GILD) and its antiviral drug remdesivir. In a nutshell, there's a lot to be hopeful about when it comes to Synairgen's new therapy, but that doesn't mean you should rush to sell your Gilead shares.
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus™ (brexucabtagene autoleucel, formerly KTE-X19), the first and only approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The approval of this one-time therapy follows a priority review and FDA Breakthrough Therapy Designation and is based on results of ZUMA-2, a single-arm, open-label study in which 87 percent of patients responded to a single infusion of Tecartus, including 62 percent of patients achieving a complete response (CR). Among patients evaluable for safety, 18 percent experienced Grade 3 or higher cytokine release syndrome (CRS) and 37 percent experienced Grade 3 or higher neurologic toxicities.
Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports second-quarter 2020 results.
An important question for large-cap investors right now is whether the current market uncertainty caused by Covid-19 will affect the share prices of companies...
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) announced today the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Jyseleca® (filgotinib 200 mg and 100 mg tablets), an investigational, once-daily, oral, selective JAK1 inhibitor for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). The CHMP positive opinion is a scientific recommendation to the European Commission to grant marketing authorization in Europe.
Investors have flocked to several small stocks with promising experimental COVID-19 therapies or SARS-CoV-2 vaccine candidates. Both rely on projections of what a company's earnings will be in the future.
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Contrarian value investors are always on the look-out for shares that the market has overlooked. In times of economic uncertainty - when stock prices become er...
Diodes Incorporated (Nasdaq: DIOD) today announced the availability of the automotive-compliant ZXTP56060FDBQ and ZXTP56020FDBQ dual PNP transistors. These new products provide OEMs with a highly efficient solution for controlling matrix LED light clusters.